IGM Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.39
- Today's High:
- $7.7492
- Open Price:
- $7.61
- 52W Low:
- $6.45
- 52W High:
- $28.2
- Prev. Close:
- $7.67
- Volume:
- 181278
Company Statistics
- Market Cap.:
- $406.81 million
- Book Value:
- 4.903
- Revenue TTM:
- $1.67 million
- Operating Margin TTM:
- -14845.07%
- Gross Profit TTM:
- $1.07 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.21%
- Return on Equity TTM:
- -73.92%
Company Profile
IGM Biosciences Inc had its IPO on 2019-09-18 under the ticker symbol IGMS.
The company operates in the Healthcare sector and Biotechnology industry. IGM Biosciences Inc has a staff strength of 289 employees.
Stock update
Shares of IGM Biosciences Inc opened at $7.61 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.39 - $7.75, and closed at $7.53.
This is a -1.83% slip from the previous day's closing price.
A total volume of 181,278 shares were traded at the close of the day’s session.
In the last one week, shares of IGM Biosciences Inc have increased by +8.03%.
IGM Biosciences Inc's Key Ratios
IGM Biosciences Inc has a market cap of $406.81 million, indicating a price to book ratio of 2.5826 and a price to sales ratio of 1136.7148.
In the last 12-months IGM Biosciences Inc’s revenue was $1.67 million with a gross profit of $1.07 million and an EBITDA of $-241114000. The EBITDA ratio measures IGM Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IGM Biosciences Inc’s operating margin was -14845.07% while its return on assets stood at -29.21% with a return of equity of -73.92%.
In Q2, IGM Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 22.4%.
IGM Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IGM Biosciences Inc’s profitability.
IGM Biosciences Inc stock is trading at a EV to sales ratio of 583.1817 and a EV to EBITDA ratio of -1.8741. Its price to sales ratio in the trailing 12-months stood at 1136.7148.
IGM Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $480.66 million
- Total Liabilities
- $44.30 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $3.91 million
- Dividend Payout Ratio
- 0%
IGM Biosciences Inc ended 2024 with $480.66 million in total assets and $0 in total liabilities. Its intangible assets were valued at $480.66 million while shareholder equity stood at $258.61 million.
IGM Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $44.30 million in other current liabilities, 528000.00 in common stock, $-698558000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $150.70 million and cash and short-term investments were $386.87 million. The company’s total short-term debt was $6,881,000 while long-term debt stood at $0.
IGM Biosciences Inc’s total current assets stands at $401.76 million while long-term investments were $0 and short-term investments were $236.17 million. Its net receivables were $0 compared to accounts payable of $4.94 million and inventory worth $0.
In 2024, IGM Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $3.91 million.
Comparatively, IGM Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.53
- 52-Week High
- $28.2
- 52-Week Low
- $6.45
- Analyst Target Price
- $22.09
IGM Biosciences Inc stock is currently trading at $7.53 per share. It touched a 52-week high of $28.2 and a 52-week low of $28.2. Analysts tracking the stock have a 12-month average target price of $22.09.
Its 50-day moving average was $8.74 and 200-day moving average was $14.57 The short ratio stood at 26.43 indicating a short percent outstanding of 0%.
Around 3679.5% of the company’s stock are held by insiders while 5718% are held by institutions.
Frequently Asked Questions About IGM Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company’s product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin’s lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.